10 Best Short Squeeze Stocks to Buy According to Analysts

6. ArriVent BioPharma, Inc. (NASDAQ:AVBP)

Short % of Float: 15.37%

Number of Hedge Fund Holders: 9

Analysts Upside Potential: 85.71%

ArriVent BioPharma, Inc. (NASDAQ:AVBP), based in Newtown Square, Pennsylvania, specializes in identifying and developing biopharmaceutical treatments sourced from global research hubs. The company focuses on oncology, as it leverages partnerships with international drug developers to advance promising therapies. Commercialization is boosted with the company capitalizing on late-stage drug candidates. The company prioritizes global collaboration, serving the United States, China, and Europe.

ArriVent BioPharma, Inc. (NASDAQ:AVBP) is gaining traction as a potential short-squeeze investment, with a short interest of 15.37%. The company raised $183.2 million through IPO after deducting underwriting discounts, commissions, and other offering expenses. Subsequently, the company’s R&D expenses grew from $64.9 million to $79.0 million between 2023 and 2024, suggesting optimal use of funds for better candidate delivery. Accordingly, ArriVent anticipates 2025 updates for EGFR PACC plans, ARR-217 IND filing, and firmonertinib Phase 3 top-line data release, translating to a positive outlook in the market.

The institutional exposure is moderate, with nine hedge funds from the Insider Monkey Q4 2024 database invested in ArriVent BioPharma, Inc. (NASDAQ:AVBP). Analysts are optimistic, rating the stock a Buy with an 85.71% upside potential. The one-year price target stands at $39. The current price is $21, attracting investors looking for the best short-squeeze stocks.